George Melvin, Selvarajan Sandhiya, S Suresh-Kumar, Dkhar Steven A, Chandrasekaran Adithan
Division of Clinical Pharmacology, JIPMER, Pondicherry, India.
Curr Clin Pharmacol. 2013 May;8(2):115-23. doi: 10.2174/1574884711308020004.
The last decade has witnessed a greater transparency in clinical research with the advent of clinical trial registries. The aim of the study was to describe the trends in the globalization of clinical trials in the last five years. We performed an internet search using the WHO International clinical trials registry platform (WHO ICTRP) to identify the clinical trials conducted from January 2007 to December 31, 2011 among 25 countries. Among the 25 countries, the United States, Japan and Germany occupy the top positions in the total number of clinical trials conducted. Clinical trials in the US (36312) constituted 31.5% of the total number of trials performed during this period. However over a period of five years both US and Western Europe appear to show a decline, while the emerging countries show a rise in clinical trials registered. Among the emerging countries China, India and Republic of Korea are most active regions involved in clinical trials. Cancer, diabetes and respiratory diseases were most widely researched areas overall. Although the study confirms the transition in the clinical trials research towards emerging countries, the developed regions of the world still contribute to more than 70% of the trials registered worldwide.
过去十年,随着临床试验注册机构的出现,临床研究的透明度有所提高。本研究的目的是描述过去五年临床试验全球化的趋势。我们利用世界卫生组织国际临床试验注册平台(WHO ICTRP)进行了一项网络搜索,以确定2007年1月1日至2011年12月31日期间在25个国家开展的临床试验。在这25个国家中,美国、日本和德国在开展的临床试验总数中位居前列。美国的临床试验(36312项)占这一时期开展的试验总数的31.5%。然而,在五年的时间里,美国和西欧的临床试验数量似乎都在下降,而新兴国家注册的临床试验数量则在上升。在新兴国家中,中国、印度和韩国是参与临床试验最活跃的地区。癌症、糖尿病和呼吸系统疾病是总体上研究最广泛的领域。尽管该研究证实了临床试验研究向新兴国家的转变,但世界发达地区仍占全球注册试验的70%以上。